Search results
Showing 16 to 30 of 62 results for rheumatology
Evidence-based recommendations on tocilizumab (RoActemra) for treating giant cell arteritis in adults.
Summary of the evidence on rituximab (MabThera) for treating skin involvement in systemic sclerosis to inform local NHS planning and decision-making
Organisation: Royal Derby Hospital and British Society for Rheumatology Published date: January 2017
This quality standard covers the assessment and management of chronic kidney disease in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.
In development [GID-TA11352] Expected publication date: 26 February 2025
Etanercept and efalizumab for the treatment of adults with psoriasis (TA103)
Evidence-based recommendations on etanercept (Enbrel) for treating severe psoriasis in adults.
directly to the NICE Quality Standard on education and self-management rheumatology teams are being audited against these standards HCP...
Evidence-based recommendations on certolizumab pegol (Cimzia) and secukinumab (Cosentyx) for treating active psoriatic arthritis in adults.
Tofacitinib for treating juvenile idiopathic arthritis (TA735)
Evidence-based recommendations on tofacitinib for treating juvenile idiopathic arthritis.
Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA543)
Evidence-based recommendations on tofacitinib (Xeljanz) for treating active psoriatic arthritis in adults after inadequate response to DMARDs.
Evidence-based recommendations on ustekinumab (Stelara) for treating active psoriatic arthritis in adults.
NICE guidance accredited decisions - status and term dates of NICE accredited guidance producers.
Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA803)
Evidence-based recommendations on risankizumab (Skyrizi) for treating active psoriatic arthritis in adults.
Evidence-based recommendations on certolizumab pegol (Cimzia) for treating severe active rheumatoid arthritis in adults who have had a tumour necrosis factor-alpha inhibitor.
Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (TA373)
Evidence-based recommendations on abatacept (Orencia), adalimumab (Humira), etanercept (Enbrel) and tocilizumab (RoActemra) for treating juvenile idiopathic arthritis in children, young people and adults.